Shots:
- Ipsen has reported topline P-III (E-BEOND & C-BEOND) trial results assessing Dysport (abobotulinumtoxinA) vs PBO in a total of 1,510 adults with episodic & chronic migraine, respectively
- Both trials met their 1EP, with a reduction in monthly migraine days vs PBO & demonstrated a favorable safety profile; detailed results will be presented at a future scientific conference
- Dysport is an injectable botulinum neurotoxin type A that inhibits nerve impulse transmission to reduce muscle contractions
Ref: Globenewswire | Image: Ipsen | Press Release
Related News: Ipsen to Acquire Memo Therapeutics for >€700M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
